NCT05560724 Network Properties As Biomarkers for Non-Invasive Brain Stimulation (NIBS) After Stroke
| NCT ID | NCT05560724 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Stroke, Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 81 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 81 participants in total. It began in 2022-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study will evaluate the potential of cortico-cerebellar network properties derived from neuroimaging in a group of chronic stroke patients to explain inter-subject variability in responsiveness to transcranial direct current stimulation (tDCS) targeting the cortico-spinal and cortico-cerebellar network.
Eligibility Criteria
Inclusion Criteria: * patients after first-ever clinical ischemic stroke in the early (\>3 month) or later chronic (\>6 months) stage of recovery * persistent motor deficit of the upper extremity * stroke location: supratentorial * age \> 18 years * written informed consent obtained Exclusion Criteria: * contraindication against MRI \& tDCS * known epilepsy, previous epileptic seizure * electric implants such as brain stimulator * medical history suggesting more than one previous stroke * severe polyneuropathy and peripheral ischemic vascular diseases; only if they critically influence sensorimotor function of the upper limb * any active drug and alcohol abuse * any active and severe psychiatric disease (such as psychosis) * severe cognitive deficits (mini mental state examination, MMSE ≤ 23) * uncontrolled other medical problems (cardiovascular diseases, instable arrhythmia, arthritis)
Contact & Investigator
Robert Schulz, PD Dr. med.
PRINCIPAL INVESTIGATOR
Universitätsklinikum Hamburg-Eppendorf
Frequently Asked Questions
Who can join the NCT05560724 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05560724 currently recruiting?
Yes, NCT05560724 is actively recruiting participants. Contact the research team at rschulz@uke.de for enrollment information.
Where is the NCT05560724 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT05560724 clinical trial?
NCT05560724 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Robert Schulz, PD Dr. med. at Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 81 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.